Affiliation:
1. The First Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730000, Gansu Province, China
2. The Cuiying Center, Lanzhou University Second Hospital, Lanzhou 730000, Gansu, China
Abstract
Background:
Epidermal Growth Factor Receptor (EGFR) and members of its homologous
protein family mediate transmembrane signal transduction by binding to a specific ligand,
which leads to regulated cell growth, differentiation, proliferation and metastasis. With the development
and application of Genetically Engineered Antibodies (GEAs), Nanobodies (Nbs) constitute a
new research hot spot in many diseases. A Nb is characterized by its low molecular weight, deep
tissue penetration, good solubility and high antigen-binding affinity, the anti-EGFR Nbs are of significance
for the diagnosis and treatment of EGFR-positive tumours.
Objective:
This review aims to provide a comprehensive overview of the information about the
molecular structure of EGFR and its transmembrane signal transduction mechanism, and discuss
the anti-EGFR-Nbs influence on the diagnosis and treatment of solid tumours.
Methods:
Data were obtained from PubMed, Embase and Web of Science. All patents are searched
from the following websites: the World Intellectual Property Organization (WIPO®), the United
States Patent Trademark Office (USPTO®) and Google Patents.
Results:
EGFR is a key target for regulating transmembrane signaling. The anti-EGFR-Nbs for targeted
drugs could effectively improve the diagnosis and treatment of solid tumours.
Conclusion:
EGFR plays a role in transmembrane signal transduction. The Nbs, especially anti-
EGFR-Nbs, have shown effectiveness in the diagnosis and treatment of solid tumours. How to increase
the affinity of Nb and reduce its immunogenicity remain a great challenge.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献